Stafne defect

From WikiMD's WELLNESSPEDIA

(Redirected from Stafne bone cavity)

Stafne defect (also known as Stafne bone cavity, Stafne bone cyst, or Stafne bone defect) is a benign, asymptomatic lingual bone depression found on the mandible. It was first described by Edward C. Stafne in 1942. The defect is usually discovered during routine radiographic examination and is typically located in the posterior region of the mandible below the mandibular canal.

Etiology[edit]

The exact cause of Stafne defect is unknown. However, it is believed to be a developmental anomaly rather than a true cyst. Some theories suggest that it may be caused by pressure exerted by submandibular gland tissue during the development of the mandible.

Clinical Features[edit]

Stafne defect is usually asymptomatic and is often discovered incidentally during routine radiographic examination. It appears as a well-defined, round or oval radiolucency in the posterior region of the mandible, below the mandibular canal. The size of the defect can vary, but it is typically between 1 and 3 cm in diameter.

Diagnosis[edit]

Diagnosis of Stafne defect is usually based on its characteristic radiographic appearance. However, other conditions such as odontogenic cysts, odontogenic tumors, and vascular malformations can have similar radiographic features, so differential diagnosis is important. In some cases, a CT scan or MRI may be used to confirm the diagnosis.

Treatment[edit]

As Stafne defect is asymptomatic and does not cause any functional impairment, treatment is usually not necessary. However, regular follow-up and radiographic monitoring are recommended to ensure that the defect does not change in size or appearance.

Prognosis[edit]

The prognosis for Stafne defect is excellent. The defect does not progress or cause any complications, and it does not require treatment unless it changes in size or appearance.

See Also[edit]

References[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.